Year: 2025
Type: article
Abstract: isplatin remains the chemotherapeutic workhorse for various solid tumors, but its Achilles' heel is nephrotoxicity.Up to one in three patients experiences some degree of cisplatin-associated acute kidney injury (CP-AKI), jeopardizing future cancer therapy options and long-term kidney health (1).Against this backdrop, Gupta and colleagues deliver the largest known human study to date assessing whether a simple, inexpensive maneuver-prophylactic intravenous (iv) magnesium-can blunt CP-AKI risk (2).Their multicenter cohort analysis of 13,719 adults treated between 2006 and 2022 across five US cancer centers provides compelling real-world evidence that magnesium matters.
Source: Kidney News
Author: Prakash Gudsoorkar
Institution: University of Cincinnati
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4411079815
